📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
38 announcements match the current filters (relevance ≥ 5).
Jagsonpal Pharma Q4 FY26 PAT Jumps 31%; Announces ₹40 Cr Buyback and 200% Dividend
Jagsonpal Pharmaceuticals reported a strong recovery in Q4 FY26 with revenue growing 10% YoY to ₹64 crores and PAT surging 31% to ₹9 crores. For the full year FY26, the company outperformed the Indian Pharmaceutical Market (IPM) with a 12.2% MAT growth compared to the industry's 7-8%. The board has approved a ₹40 crore buyback at ₹250 per share and recommended a total dividend of 200% (₹4/share), returning over ₹66 crores to shareholders. Management highlighted improved MR productivity and a strong cash position of over ₹190 crores to support future inorganic growth.
Key Highlights
Q4 FY26 PAT grew 31% YoY to ₹9 crores, while revenue increased 10% to ₹64 crores.
FY26 MAT growth of 12.2% significantly outperformed the IPM growth of 7-8%.
Approved ₹40 crore buyback at ₹250/share with no promoter participation, aiming to boost ROCE to 26%.
Total dividend of 200% (₹4 per share) announced, including a 75% special dividend.
Strong balance sheet with cash reserves exceeding ₹190 crores and a lean 11-day working capital cycle.
👀 What to Watch
Investors should take note of the company's ability to outperform the broader pharma market and its commitment to capital efficiency through buybacks and dividends. The significant improvement in return ratios (ROE/ROCE) makes it a compelling watch in the small-cap pharma space.
Jagsonpal Pharma Sets May 4, 2026, as Record Date for ₹40 Crore Buyback at ₹250/Share
Jagsonpal Pharmaceuticals has finalized May 4, 2026, as the record date for its equity share buyback. The company plans to repurchase up to 16,00,000 shares at a fixed price of ₹250 per share. The total size of the buyback is capped at ₹40 crores, representing a return of surplus cash to shareholders. This corporate action is expected to support the stock price and improve return ratios like ROE and EPS.
Key Highlights
Record date for buyback eligibility fixed as Monday, May 04, 2026
Buyback price set at ₹250 per equity share of face value ₹2 each
Total buyback size of up to 16,00,000 shares amounting to ₹40 crores
The buyback will be conducted on a proportionate basis through the tender offer route
👀 What to Watch
Investors seeking to participate in the buyback must own the shares before the ex-date to be eligible by the May 4 record date. Evaluate the premium of the ₹250 buyback price against the current market price for potential gains.
Jagsonpal Pharmaceuticals Recommends 200% Dividend of Rs 4 Per Share for FY26
The Board of Directors of Jagsonpal Pharmaceuticals has recommended a final dividend of Rs 4 per equity share for the financial year ended March 31, 2026. This payout represents 200% of the face value of Rs 2 per share. The dividend is subject to shareholder approval at the company's 47th Annual General Meeting. Specific dates for the record and payment will be announced separately following the board's recommendation.
Key Highlights
Recommended dividend of Rs 4 per equity share for the financial year 2025-26
Dividend payout represents 200% of the face value of Rs 2 per share
Final approval pending from shareholders at the upcoming 47th Annual General Meeting
Record date and tentative payment date to be intimated separately to the exchanges
👀 What to Watch
Investors should track the announcement of the record date to ensure they hold shares before that date to qualify for the Rs 4 payout. The high dividend percentage reflects a positive stance on capital distribution to shareholders.
Jagsonpal Pharma Q4 PAT Jumps 31% to ₹88 Mn; Announces ₹40 Cr Buyback & 200% Dividend
Jagsonpal Pharmaceuticals reported a strong Q4 FY26 with PAT rising 31% YoY to ₹88 Mn, supported by a 10% revenue growth. For the full year FY26, the company achieved a PAT of ₹446 Mn (+19% YoY) and maintained a robust cash balance of ₹191 Cr. The board has approved a ₹40 Cr buyback at ₹250 per share (a significant premium) and a total dividend of 200%, including a special dividend. The company continues to outperform the Indian Pharma Market (IPM) growth rates, particularly through its top 10 brands which constitute 58% of revenue.
Key Highlights
Q4 FY26 PAT grew 31% YoY to ₹88 Mn, while annual FY26 PAT rose 19% to ₹446 Mn.
Approved a ₹40 Cr buyback of 16 lakh shares at ₹250/share, representing a ~40% premium to the announcement date price.
Recommended a 200% dividend (₹4 per share), including a 75% special dividend, with a total payout of ₹26.2 Cr.
Cash and cash equivalents stood at ₹191 Cr as of March 31, 2026, up by ₹45.1 Cr during the year.
Outperformed the Indian Pharma Market (IPM) with 12.2% growth compared to 8.6% market growth on a MAT basis.
👀 What to Watch
Investors should consider the aggressive buyback and special dividend as strong indicators of management's confidence in cash flow and capital efficiency. The company's debt-free status and market outperformance make it a compelling growth-and-income play in the mid-cap pharma space.
Jagsonpal Pharma Q4 PAT Jumps 31%; Announces ₹40 Cr Buyback and 200% Dividend
Jagsonpal Pharmaceuticals reported a strong performance for Q4 FY26, with PAT rising 31% YoY to ₹88 Mn and revenue growing 9.6% to ₹642 Mn. For the full year FY26, the company achieved a PAT of ₹446 Mn (up 19%) and maintained a robust cash balance of ₹191 Cr. The board has approved a ₹40 Cr share buyback at ₹250 per share and a total dividend of 200%, including a special dividend. The company's growth continues to outpace the Indian Pharmaceutical Market (IPM), driven by its top 10 brands which contribute 58% of total revenue.
Key Highlights
Q4 FY26 PAT increased by 31% YoY to ₹88 Mn, while full-year PAT grew 19% to ₹446 Mn.
Approved a ₹40 Cr buyback of 16 lakh shares at ₹250 each, representing a significant premium to the market price.
Recommended a 200% total dividend (₹4 per share), including a 75% special dividend, with a total outlay of ₹26.2 Cr.
Cash and cash equivalents stood at a strong ₹191 Cr as of March 31, 2026, up from ₹146 Cr YoY.
Outperformed the Indian Pharmaceutical Market with 12.2% growth compared to the industry's 8.6%.
👀 What to Watch
Investors should view the aggressive capital return via buyback and special dividends as a sign of management's confidence in future cash flows. The company's debt-free status and projected improvement in ROCE to 25.7% post-buyback make it a strong candidate for long-term portfolios.
Jagsonpal Pharma Recommends Rs 4 Dividend; FY26 Revenue Grows 7% to Rs 2,872 Million
Jagsonpal Pharmaceuticals has recommended a final dividend of Rs. 4 per share (200% of face value) for the financial year ended March 31, 2026. The company's annual revenue from operations increased by 6.9% to Rs. 2,872.25 million compared to the previous year. Despite revenue growth, the annual net profit saw a decline to Rs. 430.82 million from Rs. 553.61 million in FY25. However, Q4 performance was stronger with net profit rising to Rs. 87.62 million from Rs. 65.83 million year-on-year.
Key Highlights
Recommended a final dividend of Rs. 4 per equity share (200% of face value Rs. 2)
Annual revenue from operations increased to Rs. 2,872.25 million from Rs. 2,687.16 million
Full-year net profit declined to Rs. 430.82 million compared to Rs. 553.61 million in FY25
Q4 FY26 net profit grew to Rs. 87.62 million versus Rs. 65.83 million in Q4 FY25
Annual Earnings Per Share (EPS) stood at Rs. 6.40, down from Rs. 8.26 in the previous year
👀 What to Watch
The dividend provides a decent yield, but the decline in annual profitability warrants caution. Investors should watch for margin recovery in upcoming quarters as indicated by the improved Q4 results.
Jagsonpal Pharma FY26 Revenue Up 7% to ₹2,872 Mn; Recommends 200% Dividend
Jagsonpal Pharmaceuticals reported a steady operational performance for the financial year ended March 31, 2026, with revenue from operations growing 7% YoY to ₹2,872.25 million. While the net profit for FY26 stood at ₹430.82 million compared to ₹553.61 million in FY25, the prior year's profit was significantly inflated by an exceptional gain of ₹196.87 million. On an operational basis, the profit before exceptional items and tax grew by 18.8% YoY to ₹595.97 million. The company has also announced a substantial dividend of ₹4 per share, representing a 200% payout on face value.
Key Highlights
Revenue from operations for FY26 increased to ₹2,872.25 million from ₹2,687.16 million in the previous year.
Profit before exceptional items and tax grew 18.8% YoY to ₹595.97 million, indicating strong core operational efficiency.
Q4 FY26 net profit rose to ₹87.62 million, a 33% increase compared to ₹65.83 million in Q4 FY25.
The Board recommended a final dividend of ₹4 per equity share (200% of face value of ₹2).
Earnings Per Share (EPS) for FY26 stood at ₹6.40, compared to ₹8.26 in FY25 (which included exceptional gains).
👀 What to Watch
Investors should look past the headline PAT decline as it was due to a high base effect from exceptional items last year; the core operational growth remains robust. The high dividend yield and improved quarterly margins make this a positive update for long-term holders.
Jagsonpal Pharmaceuticals Shareholders Approve Rs 40 Crore Buyback at Rs 250 Per Share
Jagsonpal Pharmaceuticals has received shareholder approval for a buyback of up to 16 lakh equity shares. The buyback is priced at Rs 250 per share, representing a total capital outlay of up to Rs 40 crore. This corporate action is designed to optimize the company's capital structure and improve Earnings Per Share (EPS). The company will communicate the specific timelines and record date for the buyback in due course.
Key Highlights
Shareholders approved the buyback of up to 16,00,000 equity shares.
The buyback price is fixed at Rs 250 per share, totaling up to Rs 40 crore.
The proposal was originally recommended by the Board on March 12, 2026.
The initiative aims to enhance shareholder value and optimize capital allocation.
Timelines and record date for the offer are yet to be announced.
👀 What to Watch
Investors should watch for the announcement of the record date to determine eligibility for the buyback. The Rs 250 price offers a potential exit or arbitrage opportunity depending on the current market price.
Jagsonpal Pharma Shareholders Approve ₹40 Crore Share Buyback at ₹250 Per Share
Jagsonpal Pharmaceuticals has received shareholder approval via postal ballot for a significant share buyback program. The company will repurchase up to 16,00,000 equity shares at a fixed price of ₹250 per share, involving a total outlay of ₹40 crores. The resolution was passed with an overwhelming majority, with 99.99% of the votes cast in favor of the proposal. This move is designed to return surplus cash to shareholders and optimize the company's capital structure.
Key Highlights
Approved buyback of up to 16,00,000 fully paid-up equity shares.
Buyback price set at ₹250 per share for equity shares with a face value of ₹2.
Total aggregate amount for the buyback is capped at ₹40 crores.
Resolution passed with 99.994% majority (4,89,18,088 votes in favor).
The buyback was conducted through a postal ballot process ending April 24, 2026.
👀 What to Watch
Investors should monitor the announcement of the record date to determine eligibility for the buyback. The offer price of ₹250 may offer an attractive premium depending on the prevailing market price.
Jagsonpal Pharma Announces Buyback of 16 Lakh Shares at ₹250 Per Share via Tender Offer
Jagsonpal Pharmaceuticals has initiated a postal ballot to seek shareholder approval for a buyback of up to 16,00,000 equity shares at ₹250 per share. The total buyback size is capped at ₹40 crores, representing 18.35% of the company's paid-up capital and free reserves as of March 2025. Crucially, promoters and the promoter group are excluded from this offer, which will be conducted via the tender offer route. The e-voting period for shareholders is scheduled from March 26, 2026, to April 24, 2026.
Key Highlights
Buyback of up to 16,00,000 equity shares (2.39% of total shares) at a price of ₹250 per share.
Total buyback size is ₹40 crores, which is 18.35% of the aggregate paid-up capital and free reserves.
The offer is via the Tender Offer route, ensuring a proportionate exit for participating shareholders.
Promoters and promoter group are specifically excluded from participating in the buyback.
15% of the buyback is reserved for small shareholders as per SEBI regulations, potentially increasing their acceptance ratio.
👀 What to Watch
Investors should compare the current market price with the ₹250 buyback price to assess the premium and potential arbitrage. Small shareholders should consider tendering their shares to benefit from the 15% reservation quota.
Jagsonpal Pharma Announces ₹40 Cr Buyback at ₹250/Share, 40% Premium
Jagsonpal Pharmaceuticals has approved a buyback of up to 16 lakh shares at a price of ₹250 per share via the tender offer route. This price represents a significant 40% premium over the current market price, with a total outlay of ₹40 crores. Promoters have decided not to participate in the buyback, which will result in their shareholding increasing from 67.2% to 68.9%. The company is utilizing its strong cash position of ₹176 crores to optimize its capital structure and expects a 400 bps improvement in ROCE.
Key Highlights
Buyback of 16 lakh equity shares at ₹250 per share, a 40% premium to market price
Total buyback size of ₹40 crores represents 18.4% of total paid-up capital and free reserves
Promoters will not participate, leading to an increase in promoter stake to 68.9%
Company maintains a strong liquidity position with ₹176 crores in free cash as of Dec 2025
Expected to improve Return on Capital Employed (ROCE) by approximately 400 basis points
👀 What to Watch
Investors should look to participate in the tender offer to realize the 40% premium on their holdings. The promoter's decision to stay invested and increase their stake post-buyback signals strong internal confidence in the company's asset-light growth model.
Jagsonpal Pharma Approves ₹40 Cr Buyback at ₹250 Per Share via Tender Offer
Jagsonpal Pharmaceuticals has approved a buyback of up to 16 lakh equity shares, representing 2.39% of its total paid-up equity capital. The buyback is priced at ₹250 per share, involving a total outlay of ₹40 crore, which constitutes 18.35% of the company's net worth as of March 2025. The process will be conducted via the tender offer route, allowing existing shareholders to participate on a proportionate basis. Notably, the promoter group has decided not to participate, which will result in their stake increasing from 67.2% to approximately 68.9% post-buyback.
Key Highlights
Buyback of up to 16,00,000 equity shares at a fixed price of ₹250 per share
Total buyback size of ₹40 crore represents 18.35% of paid-up capital and free reserves
The offer is conducted through the tender offer route on a proportionate basis
Promoters will not participate, leading to an indicative stake increase from 67.2% to 68.9%
Centrum Capital Limited has been appointed as the Manager to the Buyback
👀 What to Watch
Investors should compare the ₹250 offer price with the current market price to evaluate potential arbitrage or exit opportunities. The non-participation of promoters is a positive signal and may lead to a higher acceptance ratio for retail shareholders.
Jagsonpal Pharma Board Approves ₹40 Crore Buyback at ₹250 Per Share via Tender Route
Jagsonpal Pharmaceuticals has announced a buyback of 16 lakh shares, representing 2.39% of its total paid-up equity capital. The buyback is priced at ₹250 per share, involving a total cash outlay of ₹40 crore, which is 18.35% of the company's net worth. The process will be conducted through the tender offer route, allowing shareholders to participate on a proportionate basis. Notably, the promoters have opted not to participate, which will result in their stake increasing from 67.2% to approximately 68.9% post-completion.
Key Highlights
Buyback of up to 16,00,000 equity shares at a fixed price of ₹250 per share
Total offer size of ₹40 crore represents 18.35% of paid-up capital and free reserves
Buyback to be executed via the tender offer route on a proportionate basis
Promoters and Promoter Group will not participate in the buyback offer
Centrum Capital Limited appointed as the Manager to the Buyback
👀 What to Watch
Investors should evaluate the buyback price of ₹250 against the current market price for potential arbitrage or exit opportunities. Since promoters are not participating, the acceptance ratio for retail shareholders is likely to be higher.
Jagsonpal Pharma Q3 PAT Rises 10% to ₹12.5 Cr; Management Guides for Q4 Recovery
Jagsonpal Pharmaceuticals reported a flattish Q3 FY26 with revenue at ₹73 crores, though PAT grew 10% YoY to ₹12.5 crores. The company faced headwinds as its relevant market (RPM) grew only 3-3.5% compared to the broader pharma market's 8% growth. Management attributed the performance to internal recalibrations and leadership transitions, including a ₹2.1 crore one-time provision for the new labor code. Despite the slow quarter, the company maintains a strong cash position of ₹176 crores and expects double-digit growth to resume from Q4 FY26.
Key Highlights
Q3 FY26 Revenue stood at ₹73 crores, while 9M FY26 revenue grew 6% YoY to ₹223 crores.
PAT for the quarter increased by 10% YoY to ₹12.5 crores with margins improving 180 bps to 17.1%.
Free cash balance reached ₹176 crores, reflecting an increase of ₹15.2 crores during the quarter.
Exceptional item of ₹2.1 crores provided for past service costs related to the new labor code.
Management expects growth acceleration to double digits starting from Q4 FY26 following field force recalibration.
👀 What to Watch
Investors should monitor the promised recovery in Q4 to see if internal leadership changes and strategy refreshes translate into higher volume growth. The strong cash position and debt-free status provide a significant cushion for future expansion or acquisitions.
Jagsonpal Pharma Q3 PAT Rises 10% to ₹125 Mn; 9M PAT Up 12.5% with Strong Cash Reserves
Jagsonpal Pharmaceuticals reported a steady performance for 9MFY26 with Operating PAT growing 12.5% YoY to ₹359 million. While Q3 revenue was largely flat at ₹729 million, the company achieved significant margin expansion, with Operating PAT margins rising 160 bps to 17.1%. A key highlight is the robust cash balance of ₹1,757 million, which increased by ₹152 million during the quarter. Management has expressed confidence in stronger growth starting from Q4 FY26, backed by new product launches and focused initiatives.
Key Highlights
9MFY26 Operating PAT grew 12.5% YoY to ₹359 Mn with margins expanding 95 bps to 16.1%.
Q3FY26 Operating PAT increased 10% YoY to ₹125 Mn despite a marginal 1% dip in revenue to ₹729 Mn.
Cash and equivalents reached ₹1,757 Mn as of Dec 31, 2025, providing significant liquidity for inorganic growth.
Operating EBITDA (pre-ESOP) for 9MFY26 stood at ₹503 Mn, reflecting a 5% YoY increase.
The company provided ₹21 Mn in Q3 for potential past service costs related to the new labour code.
👀 What to Watch
Investors should monitor the company's ability to translate its high cash reserves into inorganic growth through brand or business acquisitions. The stock remains attractive due to its asset-light model and margin expansion, but the promised growth acceleration in Q4 will be a key performance indicator.
Jagsonpal Pharma Q3 PAT Rises 10% to ₹125 Mn; 9M PAT Up 12.5% with Strong Cash Position
Jagsonpal Pharmaceuticals reported a 12.5% YoY increase in Operating PAT for 9MFY26, reaching ₹359 million, despite a modest 6% revenue growth. For the Q3FY26 quarter, revenue was slightly down by 1% at ₹729 million, but Operating PAT grew by 10% to ₹125 million as margins expanded to 17.1%. The company maintains a very strong liquidity position with a cash balance of ₹1,757 million, increasing by ₹152 million during the quarter. Management remains optimistic about stronger growth starting from Q4 FY26.
Key Highlights
9MFY26 Operating PAT grew 12.5% YoY to ₹359 Mn with margins expanding 95 bps to 16.1%
Q3FY26 Revenue remained flat at ₹729 Mn, while Operating PAT rose 10% to ₹125 Mn
Cash and equivalents reached ₹1,757 Mn as of Dec 31, 2025, providing significant inorganic growth potential
Operating EBITDA margins remained resilient at 22.7% for Q3 and 22.6% for the nine-month period
Company provided ₹21 Mn for additional past service costs related to the new labor code
👀 What to Watch
Investors should focus on the company's ability to maintain high margins and its massive cash pile for potential M&A. Monitor Q4 results to see if the promised growth acceleration materializes.
Jagsonpal Pharma Q3 Operating PAT up 10% to ₹125 Mn; Cash Reserves Reach ₹1,757 Mn
Jagsonpal Pharmaceuticals reported a 12.5% YoY growth in 9MFY26 Operating PAT to ₹359 million, driven by operational discipline and a 6% revenue increase. For Q3FY26, while revenue was flat at ₹729 million, Operating PAT rose 10% YoY to ₹125 million with margins expanding to 17.1%. The company's cash balance strengthened significantly to ₹1,757 million, providing a solid foundation for future inorganic growth. Management has signaled a more aggressive growth trajectory starting from Q4 FY26.
Key Highlights
9MFY26 Operating PAT rose 12.5% YoY to ₹359 Mn; Operating PAT margins expanded by 95 bps to 16.1%
Q3FY26 Revenue remained stable at ₹729 Mn, while Operating PAT increased 10% YoY to ₹125 Mn
Cash and equivalents increased by ₹152 Mn during the quarter to reach a total of ₹1,757 Mn
Operating EBITDA (pre-ESOP) for 9MFY26 grew 5% YoY to ₹503 Mn with a 22.6% margin
A provision of ₹21 Mn was made in Q3 for past service costs related to the new labor code
👀 What to Watch
Investors should monitor the promised growth acceleration in Q4 FY26 and potential inorganic acquisitions using the company's significant cash reserves. The stock remains a steady play on domestic chronic and sub-chronic pharma segments with improving profitability.
Jagsonpal Pharma Q3 Net Profit Falls 17.8% YoY to ₹10.98 Cr; Revenue Flat at ₹72.9 Cr
Jagsonpal Pharmaceuticals reported a marginal YoY revenue decline to ₹729.45 million for the quarter ended December 31, 2025. Net profit dropped significantly by 17.8% YoY to ₹109.78 million, primarily weighed down by a ₹20.79 million exceptional charge related to new labor code transitions. While 9-month revenue showed a 6.1% growth to ₹2,230.22 million, overall profitability for the period is lower than the previous year. The company is also dealing with a ₹15.20 million GST demand, which it intends to appeal.
Key Highlights
Q3 Revenue from operations stood at ₹729.45 million vs ₹740.25 million in the previous year's quarter.
Net Profit for Q3 declined to ₹109.78 million from ₹133.57 million YoY.
Exceptional expense of ₹20.79 million recognized due to the enactment of New Labour Codes affecting employee benefits.
9-month revenue grew 6.1% YoY to ₹2,230.22 million, though 9-month profit fell to ₹320.53 million from ₹345.74 million.
Company is contesting a ₹15.20 million GST demand from the Haryana SGST office regarding ITC mismatches.
👀 What to Watch
The decline in both quarterly revenue and profit suggests a challenging operating environment; investors should wait for signs of margin recovery. Monitor the integration of the Yash Pharma business and the resolution of the GST demand for future impact.
